Castle Biosciences reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in ...

IDEAYA Biosciences (IDYA) is back in focus after reporting the first patient has been treated in a Phase 1 trial that combines IDE849 and IDE161 in DLL3 upregulated solid tumors, including small cell ...

Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab. The nimacimab monotherapy arm did ...

Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to ...

Castle Biosciences will celebrate the grand opening of its headquarters in Friendswood on March 24, according to a March 6 news release from the company.

HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief ...

The Phase 2a study results revealed that VIS-101 produced rapid and durable treatment responses with both 3 mg and 6 mg dose cohorts in patients with wet age-related macular degeneration (wet AMD).

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of ...

The John Shufeldt School of Medicine and Medical Engineering will combine clinical medicine with biomedical science and ...